Strategic Report Urges Netherlands to Prioritise Biotech or Risk Economic Stagnation
The Hague, Monday 16 February 2026 Mirroring Draghi’s EU warnings, a new Dutch strategy reveals the biotech sector contributes just 1.1% to GDP, far behind Switzerland’s 5%, demanding immediate regulatory and financial reform.
The Innovation Deficit
The release of the “Wennink Report” marks a pivotal moment for the Dutch economy, serving as a national counterpoint to the European competitiveness analysis delivered by Mario Draghi approximately 18 months ago [1][2]. Commissioned by the government, this strategic document argues that while the Netherlands possesses the requisite academic infrastructure—housing eight universities and a highly educated demographic—it is failing to translate this intellectual capital into economic output [1]. The disparity is stark when viewed through the lens of ‘red’ biotechnology (medical biotech). While this sector contributes 2.7% to the GDP of neighbouring Belgium and a formidable 5% in Switzerland, it accounts for merely 1.1% of the Dutch GDP [1]. Peter Wennink, the former CEO of ASML, has starkly warned that losing ground in this domain will have “major consequences” for the nation’s future prosperity [1].
Clinical Trials in Decline
A particularly concerning indicator of this stagnation is the sharp decline in clinical research activity, a critical phase in the life sciences value chain. Over a five-year period, the number of clinical trials conducted in the Netherlands has fallen from 282 to 210 [1]. This represents a contraction of -25.532 per cent in activity, a trend that industry experts attribute to a bureaucratic labyrinth that stifles innovation. The report explicitly identifies lengthy permit processes and complex reimbursement procedures for new drugs as primary obstacles preventing the sector from flourishing [1]. This domestic decline mirrors a broader European trend, where the continent has lost half of its clinical trials over the last decade, impacting access to innovation for thousands of patients [3].
Bridging the Lab-to-Market Gap
Despite these structural headwinds, the financial sector remains cautiously optimistic about the underlying potential of the Dutch ecosystem. Anja van Balen, a healthcare-sector banker at ABN AMRO, supports the report’s recommendation for continued investment, citing the country’s strong educational foundation [1]. However, the transition from theoretical innovation to practical application remains a critical choke point. Carla Vos, general manager of the Association for Innovative Medicines (VIG), notes that while the ecosystem is strong, the path from innovation to application “too often stalls” [1]. To rectify this, the Wennink report proposes 11 targeted projects designed to scale up the biotech sector. Central to this initiative is the creation of a ‘Biotech Nexus’, a structural intervention aimed at accelerating the trajectory from the laboratory to the patient [1]. Among the specific innovations highlighted is the development of antibodies for intranasal administration to prevent viral infections [1].
Political and Economic Imperatives
The urgency of these reforms is underscored by the broader European economic climate. At the recent EU summit in Alden Biesen on 6 February 2026, leaders discussed economic strengthening, though economists like Sander Tordoir criticised the lack of acute crisis management [2]. With Rob Jetten scheduled to assume the role of Prime Minister on 23 March 2026, the Netherlands is poised to play a significant role in forging the necessary compromises to revitalise European industry [2]. For the Dutch life sciences sector, the message from the Wennink analysis is unequivocal: the strategic growth potential will only be realised if the regulatory and financial bottlenecks are dismantled, allowing new treatments to reach patients with greater speed and predictability [1].